The anti-TRAIP polyclonal antibodies were raised against GST tagged TRAIP-N terminal fusion proteins and were affinity-purified using column coated with N-terminal MBP tagged TRAIP as previously described (29 (link)). Anti-γH2AX antibodies were previously described (30 (link)). The anti-S9.6 antibodies were from Kerafast (Boston, USA); anti-Nucleolin (C23) antibodies were from Santa Cruz (Dallas, TX, USA); anti-Ki67 antibodies were from Chemicon (Darmstadt, Germany). (Z)-4-Hydroxytamoxifen (4-OHT), anti-Actin, anti-Flag (Rabbit) and anti-Flag (Mouse; Clone M2) antibodies were from Sigma (Darmstadt, Germany); anti-pRPA32 antibodies were from Bethyl Laboratories. Shield-1 was purchased from Takara (Kanagawa, Japan). Hydroxyurea, Aphidicolin, Mitomycin C, Cisplatin, Actinomycin D, α-Amanitin, and DRB were from Sigma (Darmstadt, Germany). CX5461, ATM inhibitor (ATMi; KU55933) and ATR inhibitor (ATRi; VE821) were from SelleckChem (Houston, TX, USA). DAPI (4′,6-diamidino-2-phenylindole) and DNase I (EN0523) was from Thermo Fisher Scientific. RNase A was from Qiagen.